Abstracts tagged "Sjogren’s syndrome and cardiovascular disease"

Abstract Number: 1490 • 2017 ACR/ARHP Annual Meeting
Cardiovascular Morbidity and Mortality in Primary Sjögren Syndrome: A Systematic Review and Meta-Analysis
Aurélie Beltai¹, Cédric Lukas², Cécile Gaujoux-Viala³, Bernard Combe⁴, Jacques Morel⁴ and Thomas Barnetche⁵, ¹Department of rheumatology, Teaching hospital Lapeyronie and University of Montpellier, Montpellier, France, ²Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ³Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁴Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ⁵Rheumatology, CHU Pellegrin, Bordeaux, France, Bordeaux, France
Background/Purpose: It is well documented that patients with immune-mediated inflammatory diseases (IMID) like rheumatoid arthritis are exposed at an increased risk of cardiovascular disease. Primary…
Abstract Number: 645 • 2015 ACR/ARHP Annual Meeting
Subclinical Cardiovascular Involvement in Patients with Primary Sjögren Syndrome
Alberto Batticciotto¹, Federica Rigamonti¹, Fabiola Atzeni¹, Marco Antivalle¹, Rossella Talotta¹, Laura Boccassini¹, Luigi Gianturco², Maurizio Turiel², Andrea Doria³ and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, L. Sacco University Hospital, Milano, Italy, ²Cardiology Unit, IRCCS-Galeazzi Orthopedic Institute, Milan, Italy, ³Department of Medicine-DIMED, University of Padova, Padova, Italy
Background/Purpose: Different studies showed that systemic inflammation, elevated levels of inflammatory cytokines and immune dysregulation, typical of the inflammatory autoimmune disease, play a role in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].